PharmaCyte Biotech (PMCB) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

PMCB · Stock Price

USD 0.80-0.31 (-27.93%)

Market Cap: $8.4M

Historical price data

Market Cap: $8.4MFounded: 2003Employees: 1-10HQ: Laguna Hills, United States

Sector Ranking#125 in Drug Delivery & Formulation

Overview

PharmaCyte Biotech is a clinical-stage company developing localized cellular therapies for oncology and metabolic diseases via its Cell-in-a-Box® encapsulation technology, designed to protect implanted, engineered cells. Its most advanced program targeted locally advanced pancreatic cancer (LAPC) by activating chemotherapy at the tumor site. Since October 2022, the company has been in a strategic review, with all program spending curtailed, placing its future direction and pipeline advancement on hold pending the outcome of this evaluation.

OncologyMetabolic Disease

Technology Platform

Cell-in-a-Box® live-cell encapsulation technology uses a porous, cellulose-based capsule to protect implanted, genetically engineered human cells from immune attack, enabling localized drug activation (for cancer) or insulin production (for diabetes).

Funding History

2

Total raised:$15M

Debt$5MUndisclosedJun 15, 2021

Series A$10MUndisclosedJun 15, 2015

Opportunities

The Cell-in-a-Box® platform addresses large, unmet needs in pancreatic cancer and diabetes with a novel localized therapeutic approach.

If successfully developed, it could offer significant efficacy and safety advantages over systemic treatments.

The company's public shell also holds potential value as a vehicle for a reverse merger.

Risk Factors

The company is in a strategic review with all programs paused and minimal capital, creating extreme uncertainty.

Its technology is unproven in late-stage trials, and competitors have advanced significantly during its inactivity.

Financial viability is a immediate concern.

Competitive Landscape

PharmaCyte faces intense competition from large pharma in oncology and more advanced cell encapsulation players like Vertex (ViaCyte) in diabetes. Its dormant programs and lack of resources place it at a severe disadvantage in fast-moving therapeutic fields.